Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: The Norwegian Immunotherapy in Multiple Myeloma Study
The Norwegian immunotherapy in multiple myeloma study (NCT06855121) is currently recruiting. It targets multiple myeloma, plasma cell leukem…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
This clinical trial update describes a physician- and patient-powered cohort registry for multiple myeloma that is currently recruiting.
-
FDA approval · 2025-02-26FDA Approved: POMALIDOMIDE — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application from Apotex Corp. for pomalidomide, allowing the generic version of pomalidomide to be marketed …
-
CLINICAL_TRIALS research · 2025-02-26Clinical Trial Update: Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
This clinical trial entry reports a cost-utility analysis plan for ambulatory dose escalation of bispecific antibodies in relapsed multiple …
-
CLINICAL_TRIALS research · 2025-02-26Clinical Trial Update: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) [Phase 3]
Phase 3 trial IsKia TRIAL compares isatuximab plus KRd (Isa-KRd) to KRd alone in newly diagnosed multiple myeloma patients eligible for auto…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma [Phase 2]
Phase 2 study evaluating daratumumab in combination with pomalidomide, dexamethasone, and all-trans retinoic acid in multiple myeloma was te…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients [Phase 2]
Phase 2 trial evaluating iberdomide (CC-220) as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myelom…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease [Phase 1, Phase 2]
This clinical trial update covers a BCMA-targeted CAR-T cell therapy being explored for relapsed/refractory multiple myeloma and plasma cell…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease [Phase 1, Phase 2]
A BCMA-targeted Prime CAR-T cell therapy is being evaluated for relapsed/refractory multiple myeloma and plasma cell neoplasms in Phase 1/2 …
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) [Phase 2]
This document reports a Phase 2 clinical trial of isatuximab with dexamethasone for relapsed multiple myeloma. The study is currently active…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
An observational study in multiple myeloma reports presentation, treatment patterns, and outcomes; the study has been terminated and results…
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Rehabilitation Management for Patients with Multiple Myeloma
The document notes the completion of a clinical trial studying rehabilitation management for patients with multiple myeloma.
-
EMA withdrawal · 2025-02-19EMA Expired: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited
The EMA has expired the marketing authorization for Blenrep (belantamab mafodotin) held by GlaxoSmithKline Trading Services Limited, with th…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating all-trans retinoic acid with a KPD regimen for relapsed or refractory multiple myeloma. The study is curre…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic [Phase 2]
Phase 2 trial in relapsed and refractory multiple myeloma evaluating IPD characterized by adverse prognostic genomic abnormalities; the stud…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 study assessing safety and pharmacokinetics of XMAB24306 in combination with Daratumumab for relapsed/refractory multiple myeloma; t…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Myeloma-Developing Regimens Using Genomics (MyDRUG) [Phase 1, Phase 2]
Phase 1/2 trial named MyDRUG investigates genomics-guided regimens for relapsed or refractory multiple myeloma. The study has completed enro…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT [Phase 1, Phase 2]
A Phase 1/Phase 2 trial investigating elotuzumab with anti-LAG-3 and anti-TIGIT antibodies for multiple myeloma has been terminated.
-
EMA approval · 2025-02-13EMA Authorised: Bortezomib Fresenius Kabi (bortezomib) — Fresenius Kabi Deutschland GmbH
The European Medicines Agency authorised Bortezomib Fresenius Kabi for the treatment of multiple myeloma, with the active substance bortezom…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
This clinical trial update describes the PRO SID Project, which aims to develop and validate a patient-reported outcome screening measure fo…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Bioequivalence Studies of Dasatinib 100 Mg [Phase 4]
Phase 4 bioequivalence study of dasatinib 100 mg for multiple myeloma is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients [Phase 2]
Phase 2 study of denosumab in high-risk smoldering multiple myeloma and SLiM-CRAB positive early multiple myeloma patients has completed.
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating ESO-T01 for relapsed or refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-10Clinical Trial Update: Telehealth-based Symptom Management for Veterans Treated With Selinexor
ClinicalTrials.gov update indicates a telehealth-based symptom management study for veterans treated with selinexor is currently active but …
-
CLINICAL_TRIALS research · 2025-02-10Clinical Trial Update: Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer [NA]
A clinical trial is being developed to test an intervention that combines hypnosis and virtual reality to support patients with hematologic …